Quarterly report pursuant to Section 13 or 15(d)

Liquidity and Financial Condition (Details Narrative)

v3.21.2
Liquidity and Financial Condition (Details Narrative) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended
Jun. 24, 2020
May 01, 2020
Nov. 30, 2021
Jun. 02, 2020
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2020
Jun. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Mar. 31, 2021
Asset Acquisition [Line Items]                      
Net loss         $ 100,000 $ 1,098,000 $ (120,000) $ (240,000) $ 1,198,000 $ (360,000)  
Accumulated deficit         180,475,000       180,475,000   $ 179,277,000
Working capital         $ 13,943,000       13,943,000   $ 8,905,000
Cash received from sale of Micromed                 0 610,000  
Forgiveness of PPP Loan                 723,000 (0)  
Stock issued during period, shares         855,500            
Gross proceeds from issuance of stock         $ 7,202,000            
Net proceeds         $ 6,902,000       6,892,000 $ 0  
Subsequent Event [Member]                      
Asset Acquisition [Line Items]                      
Stock issued during period, shares     94,600                
Gross proceeds from issuance of stock     $ 700,000                
Net proceeds     $ 678,000                
November 2018 Common Stock Purchase Warrants [Member]                      
Asset Acquisition [Line Items]                      
Proceeds from exercise of warrants       $ 1,799,000              
Paycheck Protection Program [Member] | States Bank In Atlanta [Member]                      
Asset Acquisition [Line Items]                      
Proceeds from Loans   $ 1,310,000                  
Debt Instrument, Maturity Date   Apr. 29, 2022                  
Debt Instrument, Interest Rate, Stated Percentage   1.00%                  
Forgiveness of PPP Loan                 $ 7,230    
Asset Purchase Agreement [Member]                      
Asset Acquisition [Line Items]                      
Aggregate sale price of Micromed division $ 850,000                    
Cash received from sale of Micromed 610,000                    
Credit received for future testing services from sale of Micromed 100,000                    
Sale of assets, amount held in escrow 60,000                    
Accounts receivable remaining from sale of asset $ 81,000